Trial Profile
A phase II trial to investigate the efficacy of BPM 31510 in patients with renal cancer
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 16 Mar 2023
Price :
$35
*
At a glance
- Drugs Ubidecarenone (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 08 Feb 2023 According to a BPG Bio media release, Berg Pharma has been acquired by BPG Bio.
- 10 Sep 2015 New trial record